The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Guideline for Management of Vasculitis Syndrome (JCS 2008) - Digest Version -
Open accessAbstract
Background of the Guideline1 Classification of Vasculitis Syndromes Vasculitis syndromes are classified, according to the size of the affected vessels, into large-vessel, medium-vessel, and small-vessel vasculitis (Table 1).Large-sized vessel vasculitis, ie, vasculitis occurring in the aorta and its major branches to the extremities, the head and the neck, includes Takayasu arteritis and temporal arteritis.Medium-sized vessel vasculitis, ie, vasculitis occurring in the major arteries and their branches to the visceral organs, includes polyarteri-tis nodosa (PAN), Kawasaki disease, and Buerger disease.Small-sized vessel vasculitis occurs in the arterioles, capillaries, and venules.In some cases, small arteries are also affected.Small-sized vessel vasculitis is classified according to the involvement of immune complexes.Vasculitis involving immune complexes include Henoch-Schönlein purpura, essential cryoglobulinemia, and malignant rheumatoid arthritis (MRA) (rheumatoid vasculitis).Small-sized vessel vasculitis not involving immune complexes include microscopic polyangiitis (MPA), Wegener's granulomatosis, and allergic granulomatous angiitis.Since these three conditions are associated with the presence of marker antibodies, ie, *Described in the present guidelines.The six underlined diseases are investigated by the Specific Disease Study Group of the MHLW.Polyarteritis nodosa and microscopic polyangiitis were categorized collectively as "periarteritis nodosa" until 2005.From 2006 on, these diseases have been clearly distinguished.ANCA, antineutrophil cytoplasmic antibodies; MHLW, Ministry of Health, Labour and Welfare.Wegener's granulomatosis Buerger disease Takayasu arteritis Malignant rheumatoid arthritis Microscopic polyangiitis + Polyarteritis nodosa JCS Joint Working Group II.Systemic signs/symptoms: Body weight often de-creases due to persistent high fever.Patients complain of vague symptoms such as weakness and generalized malaise. 2) Localized Visceral Signs/SymptomsThe visceral signs/symptoms of vasculitis syndromes arise simultaneously (or sequentially) as signs/symptoms associated with multiple organs.Visceral signs/symptoms are caused by ischemia or hemorrhage due to injury of affected blood vessels, and differ in nature by size of the affected blood vessels (Table 2). i) Visceral Signs/Symptoms of Large-and Medium-Sized Vessel Vasculitis (Table 2-I):Since large-and medium-sized vessels run from the aorta to visceral organs, the signs/symptoms of vasculitis result from injury to organs supplied by the affected blood vessels, and include pulse deficit, jaw claudication, loss of vision, and acute abdomen.Injury of large-or medium-sized vessels in the kidneys causes rapidly progressive hypertension and renal insufficiency. ii) Visceral Signs/Symptoms of Small-Sized VesselVasculitis (Table 2-II): The characteristic skin finding of small-sized vessel vasculitis is palpable purpura that often develops in the lower limbs.Mononeuritis multiplex is a clinical manifestation of vasculitis of medium-or small-sized vessel arteries feeding the affected nerves.It may manifest as sensory disturbance such as hyperesthesia or hypoesthesia, and, when progressive, leads to motor disturbance that may cause a drop hand or foot.The clinical features of vasculitis in small-sized vessels of the kidneys include those of nephritis, such as hematuria, proteinuria, and cylindruria.When pulmonary alveolar hemorrhage due to arteriolitis or venulitis develops, patients may expectorate bloody, foamy sputum.JCS Joint Working Group (1) Pneumocystis Pneumonia 1) Criteria for Prophylaxis Against Pneumocystis Pneumonia in Patients With Autoimmune Disease Patients requiring primary prophylaxis • Patients aged ≥50 years • Patients receiving glucocorticoid Patients receiving prednisolone (PSL) at ≥1.2 mg/kg/day or receiving ≥0.8 mg/kg/day PSL in combination with immunosuppressive drugs.Criteria for discontinuation of prophylaxis: Patients whose dose of PSL is ≤0.4 mg/kg/day.• Patients receiving immunosuppressive drugs Patients receiving ≥0.8 mg/kg/day PSL or with a peripheral lymphocyte count of ≤500 / μL.Criteria for discontinuation of prophylaxis: Patients whose dose of PSL is ≤0.4 mg/kg/day or with a peripheral lymphocyte count of ≥500 / μL over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Cited by
Nakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S., Nomura, A., Yoshida, S., & Nishimoto, N. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211878 · Cited by 344
Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment
Borchers, A. T., & Gershwin, M. E. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.01.003 · Cited by 256
Metadata
- Authors
- JCS Joint Working Group
- Venue
- Circulation Journal
- Publisher
- Japanese Circulation Society
- Published
- 2011
- Volume
- 75
- Issue
- 2
- Pages
- 474-503
- ISSN
- 1346-9843 (ISSN-L)
- 1347-4820
- OpenAlex
- W4240583319
- Cited by
- 162
- References
- 1
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guideline for Management of Vasculitis Syndrome (JCS 2008) - Digest Version -. https://app.cochat.ai/papers/10.1253/circj.cj-88-0007
- The paper
- JCS Joint Working Group. (2011). Guideline for Management of Vasculitis Syndrome (JCS 2008) - Digest Version -. Circulation Journal. https://doi.org/10.1253/circj.cj-88-0007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.